Aurora Cannabis (ACB) Cash from Financing Activities (2017 - 2025)
Aurora Cannabis (ACB) posted quarterly Cash from Financing Activities of $1.3 million for Q4 2025, up 259.16% year-over-year from $348312.4 in Q4 2024, and up 226.32% quarter-over-quarter from -$990318.3 in Q1 2025.
Aurora Cannabis (ACB) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Cash from Financing Activities for 9 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 259.16% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $2.4 million (up 138.95% YoY), while the FY2026 annual figure was $3.6 million, up 212.29% from the prior year.
- Cash from Financing Activities climbed to $1.3 million in Q4 2025 per ACB's latest filing, from -$990318.3 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $129.9 million in Q1 2021 and bottomed at -$48.1 million in Q2 2021.
- Historically, Cash from Financing Activities has averaged $12.5 million across 5 years, with a median of $232500.0 in 2024.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities sank 1215.42% — and 2025, when it surged 259.16%.
- Aurora Cannabis' Cash from Financing Activities stood at -$5.9 million in 2021, then sank by 680.38% to -$46.0 million in 2022, then jumped by 124.23% to $11.1 million in 2023, then tumbled by 107.06% to -$786000.0 in 2024, then soared by 259.16% to $1.3 million in 2025.
- Business Quant data shows ACB's Cash from Financing Activities at $1.3 million in Q4 2025, -$990318.3 in Q1 2025, and -$786000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Aurora Cannabis | 243.01 Mn | 170.70 Mn | 25.75 Mn | 3.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | -990,318.31 |
| Mar 31, 2025 | -990,318.31 |
| Dec 31, 2024 | -786,000.00 |
| Dec 31, 2024 | -786,000.00 |
| Sep 30, 2024 | 2.90 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | -4.61 Mn |
| Jun 30, 2024 | -4.61 Mn |
| Mar 31, 2024 | -3.62 Mn |
| Mar 31, 2024 | -3.62 Mn |
| Dec 31, 2023 | 11.13 Mn |
| Dec 31, 2023 | 11.13 Mn |
| Sep 30, 2023 | 2.79 Mn |
| Sep 30, 2023 | 2.79 Mn |
| Dec 31, 2022 | -45.96 Mn |
| Dec 31, 2022 | -45.96 Mn |
| Sep 30, 2022 | 40.18 Mn |
| Sep 30, 2022 | 40.18 Mn |